Holen Sie sich die Stockscreener-App
5.37
0.00%
0.00
Schlusskurs vom Vortag:
$5.37
Offen:
$5.32
24-Stunden-Volumen:
625.21K
Relative Volume:
0.35
Marktkapitalisierung:
$1.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-129.48M
KGV:
-9.6168
EPS:
-0.5584
Netto-Cashflow:
$-106.97M
1W Leistung:
+2.09%
1M Leistung:
-0.74%
6M Leistung:
-4.45%
1J Leistung:
+50.00%
1-Tages-Spanne:
$5.31
$5.39
1-Wochen-Bereich:
$5.21
$5.56
52-Wochen-Spanne:
$3.34
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.37 | 1.13B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara Announces New Employment Inducement GrantAugust 20, 2026 - BioSpace
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Outlook Update - dars.gov.et
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11 - Moomoo
Savara (SVRA) Advances 2.09% to $5.38 as Aerosol Therapy Momentum BuildsStock Analysis - Vinanet
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Pipeline InvestmentPeak Earnings Alert - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Triple Top - vinanet.vn
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - marketbeat.com
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in SightPrice Momentum Stocks - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Revenue Weighted - Vinanet
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. Announces Q2 2026 Financial Results with Increased Net Losses - Kalkine Media
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Q2 loss widens as operating expenses rise - TradingView
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary - TradingView
BRIEF-Savara Q2 Net Income USD -40.228 Million - TradingView
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC - MarketBeat
Savara Inc (YB4P.SG) recent insider transactions - au.finance.yahoo.com
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 88.90% Potential Upside - DirectorsTalk Interviews
Savara investors brace for earnings ahead of crucial FDA review By Investing.com - Investing.com Nigeria
Savara (SVRA) to Announce Quarterly Earnings on Wednesday - MarketBeat
SVRA Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA) - Seeking Alpha
Savara's upcoming APAP BLA filing seen as key c... - Pluang
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
SVRA Q1 2026 Earnings: Wider Loss Than Expected as Pre-Revenue Biotech Navigates Pipeline CostsEarnings Weakness Phase - vinanet.vn
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA - MarketBeat
Savara Inc. (SVRA) Slips to $5.44 as Rare Disease Biotech Holds Support ZoneEase of Movement - dars.gov.et
Savara Inc. (SVRA) Gains 2% as Shares Test Key Resistance LevelsVolume Dry Up - dars.gov.et
Savara secures European, Australian patents for MOLBREEVI By Investing.com - Investing.com Nigeria
SVRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Savara Inc. $SVRA Shares Bought by Eversept Partners LP - marketbeat.com
SVRA|Savara Inc|Price:5.435|Chg%:-0.075 - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA - MarketBeat
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Jun 22 '26 |
Sale |
5.68 |
394,528 |
2,241,432 |
536,032 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):